Read by QxMD icon Read

Advances in Therapy

László Gulácsi, Zsombor Zrubka, Valentin Brodszky, Fanni Rencz, Rieke Alten, Zoltán Szekanecz, Márta Péntek
INTRODUCTION: Synthesis of evidence on the long-term use of first-line biologic therapy in patients with early rheumatoid arthritis (RA) is required. We compared the efficacy of up to 5 years' treatment with first-line tumor necrosis factor inhibitors (TNFis) versus other treatment strategies in this population. METHODS: Previous systematic reviews, PubMed and the Cochrane Central Register of Controlled Trials were searched for randomized controlled trials (RCTs) involving treatment of methotrexate-naïve RA patients with first-line TNFis...
January 12, 2019: Advances in Therapy
Katsuyoshi Suzuki, Naomi Otsuka, Hiroko Hizaki, Masayo Hashimoto, Yasuaki Kuwayama
In the original publication, the range to derive the P values is incorrectly represented in Table 2 and Table 3. The corrected tables are provided below.
January 8, 2019: Advances in Therapy
Hayley M de Freitas, Tetsuro Ito, Monica Hadi, Gemma Al-Jassar, Mickaël Henry-Szatkowski, Beenish Nafees, Andrew J Lloyd
INTRODUCTION: Various treatment options are available for metastatic hormone-sensitive prostate cancer. This study aimed to quantify how men with prostate cancer in the United Kingdom (UK), Germany, and Spain perceive the risks and benefits of hypothetical abiraterone acetate plus prednisone treatment and docetaxel-based chemotherapy treatment options. METHODS: A targeted literature review, exploratory interviews with prostate cancer patients and oncologists, and pre-test interviews were used to develop a discrete choice experiments (DCE)...
January 7, 2019: Advances in Therapy
Hidenobu Tanihara, Takahiko Kakuda, Tetsuro Sano, Takashi Kanno, Ryosuke Imada, Wataru Shingaki, Ryoji Gunji
INTRODUCTION: To evaluate the safety and intraocular pressure (IOP)-lowering effects of a ripasudil 0.4% ophthalmic solution in Japanese patients with glaucoma and ocular hypertension (OH) as a post-marketing surveillance. METHODS: This was a 2-year prospective observational study in patients with glaucoma or OH who had not previously received ripasudil. Patients registered in the study using a central internet-based system from June 1, 2015 to April 30, 2017. Data on adverse drug reactions (ADRs) and IOP were collected and analysed from the first 3 months of ripasudil treatment...
January 4, 2019: Advances in Therapy
Leigh Perreault, Helena Rodbard, Virginia Valentine, Eric Johnson
The progressive nature of type 2 diabetes (T2D) means that many patients will require basal insulin therapy at some point in the course of the disease due to β-cell failure. As basal insulin primarily targets fasting plasma glucose, patients may still experience considerable postprandial glucose excursions and therefore require an additional agent to achieve good glycemic control. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide an alternative to prandial insulin, with the benefits of fewer daily injections, and a lower risk of hypoglycemia and weight gain...
January 4, 2019: Advances in Therapy
Koki Sato, Nobuhito Taniki, Ryo Kanazawa, Motonori Shimizu, Shigeto Ishii, Hideko Ohama, Masashi Takawa, Hiroaki Nagamatsu, Yasuharu Imai, Shuichiro Shiina
INTRODUCTION: Radiofrequency ablation (RFA) has been accepted as safe and effective for treating early-stage hepatocellular carcinoma (HCC). However, it often causes severe pain. Therefore, in this study, we performed RFA under deep sedation and investigated its efficacy and safety. METHODS: We conducted a retrospective study including 511 HCC patients who received approximately 886 RFA treatments between December 2014 and November 2016 at our institution. Respiratory depression was defined as oxygen saturation of below 90%; and severe body movement was defined as movement caused by pain, which was managed by lowering the power of the generator...
January 3, 2019: Advances in Therapy
Jie Xiong, Guifang Zhao, Shengli Yang, Jing Chen
INTRODUCTION: Aprepitant, a selective neurokinin-1 receptor antagonist approved for prevention of chemotherapy-induced nausea and vomiting (CINV), is an inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme, which is involved in the clearance of several chemotherapeutic agents. Here we evaluated the efficacy and toxicity of a combination of aprepitant, palonosetron, and dexamethasone as antiemetic prophylaxis in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy, and examined the potential of aprepitant to affect the pharmacokinetics of ifosfamide, which is primarily metabolized by CYP3A4...
January 3, 2019: Advances in Therapy
Stefano Omboni, Massimo Volpe
Blood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin-angiotensin-aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10% the incidence of CV mortality, non-fatal myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients...
December 27, 2018: Advances in Therapy
Lauren J Lee, Qian Li, Marianna Bruno, Birol Emir, Brian Murphy, Surbhi Shah, Matthew Reynolds, Nick Marchant, Peter W Park
INTRODUCTION: Varenicline (VAR) is an effective smoking-cessation therapy compared to the commonly used nicotine-replacement therapy patch (NRT-P). However, comparative real-world evidence on smoking-cessation therapies is limited, especially for economic outcomes. METHODS: Using national claims databases (2012-2016) in the United States (US), adults initiating VAR or NRT-P without use of any other smoking-cessation products were followed for up to 1 year on a quarterly basis...
December 19, 2018: Advances in Therapy
Lourdes Garza-Ocañas, Jorge González-Canudas, Eduardo Tamez-de la O, Christian Badillo-Castañeda, Marco Vinicio Gómez-Meza, Yulia Romero-Antonio, Aarón Molina-Pérez, Ana Gabriela Amador-Hernández
INTRODUCTION: Metformin tablets may be challenging to swallow not only for those patients with dysphagia but also for children and the elderly. A metformin solution was developed for easier administration and flexible dose adjustment mantained with the same bioavailability of tablets. The objective of this study was to assess the single-dose oral bioavailability of metformin hydrochloride administered as an oral solution (500 mg/5 mL) compared with metformin hydrochloride 500 mg tablets in fasting Mexican healthy volunteers...
December 18, 2018: Advances in Therapy
Angelo Maria Minnella, Matteo Federici, Valeria Pagliei, Angela Lanza, Gloria Gambini, Carmela Grazia Caputo, Benedetto Falsini, Aldo Caporossi
INTRODUCTION: To evaluate the short-term efficacy and safety of intravitreal dexamethasone implant (IDI) in patients with macular oedema associated with diabetic retinopathy (DR) and retinal vein occlusion (RVO) using enhanced-depth image optical coherence tomography (EDI-OCT) and to estimate the effect of dexamethasone on the choroid and the retinal vascular network using OCT angiography (OCTA). METHODS: Fifteen eyes in 15 patients with macular oedema secondary to diabetes (DR, n = 8) or retinal vein occlusion (RVO, n = 7) were treated with intravitreal injection of sustained-release IDI...
December 18, 2018: Advances in Therapy
Marina E Cazzaniga, Elisabetta Munzone, Guido Bocci, Noémia Afonso, Patricia Gomez, Sven Langkjer, Edgar Petru, Xavier Pivot, Pedro Sánchez Rovira, Piotr Wysocki, Valter Torri
INTRODUCTION: Metronomic chemotherapy (mCHT) is a treatment regimen in which drugs are administered frequently or continuously and that maintains low, prolonged, and pharmacologically active plasma concentrations of drugs to avoid toxicity associated with traditional chemotherapy regimens, while achieving tumor response. Despite the increasing use of mCHT in patients with metastatic breast cancer (MBC) and the endorsement of mCHT in guidelines, no consensus exists about which patients may substantially benefit from mCHT, which agents can be recommended, and in which treatment setting mCHT is most appropriate...
December 18, 2018: Advances in Therapy
Cristina Esquinas, Javier C Angulo
INTRODUCTION: Adjustable transobturator male system (ATOMS) is a surgical device developed to treat male stress urinary incontinence (SUI) after prostate surgery. The objective was to assess the effectiveness of the ATOMS device to treat male SUI as described in the literature. METHODS: Two independent reviewers identified studies eligible for a systematic review and meta-analysis of various sources written in English, German and Spanish, using the databases PubMed, EMBASE and Web of Science...
December 17, 2018: Advances in Therapy
Johan van Cleemput, Andrea Sonaglioni, Wim A Wuyts, Monica Bengus, John L Stauffer, Sergio Harari
The presence of rare comorbidities in patients with cardiovascular disease (CVD) presents a diagnostic challenge to cardiologists. In evaluating these patients, cardiologists are faced with a unique opportunity to shorten diagnosis times and direct patients towards correct treatment pathways. Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is an example of a rare disease where patients frequently demonstrate comorbid CVD. Both CVD and IPF most commonly affect a similar patient demographic: men over the age of 60 years with a history of smoking...
December 15, 2018: Advances in Therapy
Hong-Xia Wu, Min Zhu, Xiao-Feng Xiong, Jia Wei, Kai-Quan Zhuo, De-Yun Cheng
INTRODUCTION: Cystic fibrosis (CF) is a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time. The combination of a cystic fibrosis transmembrane conductance regulator (CFTR) corrector and potentiator has provided a benefit by decreasing sweat chloride concentration in CF for the F508del-CFTR homozygous mutation, but it remains controversial in lung function, nutritional status, clinical score and safety. METHODS: The authors performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of combination therapy on lung function, nutritional status, clinical score and safety in CF for the F508del-CFTR homozygous mutation...
December 15, 2018: Advances in Therapy
Dongkuk Park, Jihoon Yun, Su-Jeong Hwang, Su Jin Park
INTRODUCTION: Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have shown success in treating autoimmune inflammatory diseases but are associated with substantial financial burdens to the healthcare system. Biosimilars, which are highly similar to biologic agents, offer the potential to reduce the financial burden of treatment. In the case of TNF-alpha inhibitors, they may also offer improved stability and enable prolonged use. SB5, an adalimumab biosimilar, has shown equivalent efficacy and comparable safety to its reference product in clinical trials...
December 15, 2018: Advances in Therapy
Nassim Kamar, Elisabeth Cassuto, Giovanni Piotti, Mirco Govoni, Giorgia Ciurlia, Silvia Geraci, Gianluigi Poli, Gabriele Nicolini, Christophe Mariat, Marie Essig, Paolo Malvezzi, Yannick Le Meur, Valerie Garrigue, Arnaud Del Bello, Lionel Rostaing
INTRODUCTION: Different prolonged-release formulations of tacrolimus are available. To date, the pharmacokinetic (PK) profile of LCP-tacrolimus (LCPT; Envarsus® ) has not been compared with PR-Tac (Advagraf® ) in de novo kidney transplant recipients. These profiles will guide clinical recommendations for the initiation and dose titration strategies of once-daily tacrolimus formulations. METHODS: This randomized, parallel-group, open-label, multicenter PK study randomized 75 de novo, adult, white kidney transplant recipients to LCPT 0...
December 14, 2018: Advances in Therapy
Nigel S Cook, Sarthak H Nagar, Akanksha Jain, Maria-Magdalena Balp, Miriam Mayländer, Olivia Weiss, Satabdi Chatterjee
INTRODUCTION: The aim of this work was to understand how patients with non-alcoholic steatohepatitis (NASH) perceive their disease, unmet needs, and expectations regarding future treatment through online bulletin board (OBB) qualitative research. METHODS: OBB is an asynchronous online qualitative market research tool that provides an open forum for interactive discussion among participants. Patients with NASH were recruited via physician referral and completed a screener questionnaire to ensure their eligibility and willingness to participate...
December 13, 2018: Advances in Therapy
Alpesh Amin, W Richey Neuman, Melissa Lingohr-Smith, Brandy Menges, Jay Lin
INTRODUCTION: Venous thromboembolism (VTE) is a leading cause of preventable morbidity and mortality among hospitalized patients in the US. The objectives of this study were to examine VTE prophylaxis patterns and risk for VTE events during hospitalization and post-discharge among patients hospitalized for acute illnesses in the US. METHODS: Acutely ill hospitalized patients were identified from the MarketScan databases (January 1, 2012-June 30, 2015). Proportions of patients that received inpatient and/or outpatient VTE prophylaxis were determined...
December 12, 2018: Advances in Therapy
Kirill Lobastov, Ilya Schastlivtsev, Victor Barinov
INTRODUCTION: The aim of this study was to assess the impact of adding long-term micronized purified flavonoid fraction (MPFF) to standard treatment of femoropopliteal deep vein thrombosis (DVT). METHODS: This pilot, comparative, open-label study with blinded outcome assessor enrolled patients with a first episode of femoropopliteal DVT confirmed by duplex ultrasound scanning (DUS). All participants were randomly allocated to one of two treatment groups: (1) control that received a standard treatment with oral rivaroxaban, and (2) experimental that involved additional treatment with MPFF 1000 mg/day...
December 11, 2018: Advances in Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"